Integra Adds iPASSAGE Retractor

Recently, Integra Lifesciences Holdings Corporation (IART) added a tissue sparing retraction system, iPASSAGE Retractor for Minimally Invasive Surgery of the lumbar spine. The iPASSAGE system allows the surgeon to make smaller cuts, thereby reducing the time of recovery, tissue damage and blood loss.
 
Integra distributes the iPASSAGE Retractor system through Integra Spine, a part of the Orthopedics segment. The company’s spine and orthobiologics product portfolio includes spinal fusion devices; supplemental fixation systems for cervical procedures; interbody/vertebral body replacement devices to hold the graft in place to ensure a fusion; orthobiologic products for the repair and regeneration of bone in spinal and trauma surgery; and minimally invasive spine products.
 
Integra generates revenue through its three business segments: Integra NeuroSciences (neurosurgery and neurotrauma), Integra Orthopedics (burn, plastic and reconstructive surgery), and Integra Medical Instruments (basic general and specialty surgical instruments). These segments recorded year-over-year revenue growth of 7.9%, 11.7% and 0.9%, respectively, in the second quarter of 2010.
 
In the next 3 to 5 years, Integra will focus on expansion of sales distribution, new product development, leveraging synergies, and building infrastructure within the Orthopedics segment. The company also expects to leverage its existing relationships with neurosurgeons to expand its spine sales, given that 50% of spine procedures are conducted by neurosurgeons.
 
Integra develops, manufactures and markets surgical implants and medical instruments and is a world leader in regenerative medicine. The company’s products are used primarily in neurosurgery, extremity reconstruction, orthopedics, and general surgery to treat millions of patients every year.

 Its direct competitors in the Medical Instruments & Supplies industry include Medtronic Inc. (MDT) and Stryker Corp. (SYK).

Read the full analyst report on IART

Read the full analyst report on MDT

Read the full analyst report on SYK